Prado: Personalized Response-Driven Therapy In Resectable Stage Iii Melanoma

PRADO: personalized response-driven therapy in resectable stage III melanoma

PRADO: personalized response-driven surgery and adjuvant therapy in stage III melanoma

OpACIN-neo & PRADO 3-year results in stage III melanoma: personalized neoadjuvant IO benefits

The personalization of neoadjuvant immunotherapy in stage III melanoma

Neoadjuvant ipilimumab and nivolumab immunotherapy for resectable stage III melanoma

OpACIN-neo and PRADO: personalized neoadjuvant IO for melanoma based on pathologic response

Response-Driven Surgery and Adjuvant Therapy After Neoadjuvant Immunotherapy for Stage III Melanoma

Personalizing Melanoma Treatment for Stage III and Stage IV Patients

Neoadjuvant Therapy in Melanoma: The PRADO Trial - 2022 Program: Melanoma Video Library

GRACE - Global Resource for Advancing Cancer Education

AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber

European Society for Medical Oncology (ESMO)

Adjuvant Therapy for Resected Stage III Melanoma

Melanoma Care: Continued Progress With Immunotherapy in Resectable and Unresectable Disease

PeerView Oncology

Harnessing the Power of Immunotherapy in Resectable Melanoma

PeerView Oncology

FDA-MRA Approaches to Neoadjuvant Treatment in Melanoma: Session 3

Adjuvant Treatment for BRAF+ Stage III Melanoma: A Case Study to Weigh ICI Versus Targeted Therapies

Localizing Pathologic Response After Neoadjuvant Immunotherapy for Stage III Melanoma

DONIMI: neoadjuvant domatinostat in patients with melanoma based on IFN-γ signatures

Case Consult: Adjuvant Therapy Following Localized Treatment for Stage III Melanoma

Clinical trials investigating the treatment of melanoma